Primecap Management Co. CA Sells 5,290 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Primecap Management Co. CA decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 404,000 shares of the company’s stock after selling 5,290 shares during the period. Primecap Management Co. CA owned approximately 0.40% of Neurocrine Biosciences worth $46,549,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. 1832 Asset Management L.P. raised its holdings in shares of Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after acquiring an additional 504,400 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 639.6% during the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after buying an additional 363,863 shares during the last quarter. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after buying an additional 228,444 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in Neurocrine Biosciences in the 1st quarter valued at $30,342,000. Finally, Renaissance Technologies LLC lifted its stake in Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after acquiring an additional 216,500 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Royal Bank of Canada decreased their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Finally, Jefferies Financial Group lifted their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Trading Up 1.4 %

Shares of NBIX stock opened at $125.00 on Friday. The firm’s 50 day moving average is $118.48 and its 200 day moving average is $132.18. The stock has a market capitalization of $12.66 billion, a P/E ratio of 33.51 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $109.77 and a 12 month high of $157.98.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.